Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

W. Taal; H.M. Oosterkamp; A.M.E. Walenkamp; H.J. Dubbink; L.V. Beerepoot; M.C.J. Hanse; J. Buter; A.H. Honkoop; D. Boerman; F.Y.F. de Vos; W.N.M. Dinjens; R.H. Enting; M.J.B. Taphoorn; F.W.P.J. van den Berkmortel; R.L.H. Jansen; D. Brandsma; J.E.C. Bromberg; I. van Heuvel; R.M. Vernhout; B. van der Holt; M.J. van den Bent

doi:https://doi.org/10.1016/S1470-2045(14)70314-6

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

W. Taal, H.M. Oosterkamp, A.M.E. Walenkamp, H.J. Dubbink, L.V. Beerepoot, M.C.J. Hanse, J. Buter, A.H. Honkoop, D. Boerman, F.Y.F. de Vos, W.N.M. Dinjens, R.H. Enting, M.J.B. Taphoorn, F.W.P.J. van den Berkmortel, R.L.H. Jansen, D. Brandsma, J.E.C. Bromberg, I. van Heuvel, R.M. Vernhout, B. van der HoltM.J. van den Bent

Research output: Contribution to journal › Article › Academic › peer-review

609 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	943-953
Journal	lancet oncology
Volume	15
Issue number	9
DOIs	https://doi.org/10.1016/S1470-2045(14)70314-6
Publication status	Published - 2014

Access to Document

https://doi.org/10.1016/S1470-2045(14)70314-6

Cite this

Taal, W., Oosterkamp, H. M., Walenkamp, A. M. E., Dubbink, H. J., Beerepoot, L. V., Hanse, M. C. J., Buter, J., Honkoop, A. H., Boerman, D., de Vos, F. Y. F., Dinjens, W. N. M., Enting, R. H., Taphoorn, M. J. B., van den Berkmortel, F. W. P. J., Jansen, R. L. H., Brandsma, D., Bromberg, J. E. C., van Heuvel, I., Vernhout, R. M., ... van den Bent, M. J. (2014). Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. lancet oncology, 15(9), 943-953. https://doi.org/10.1016/S1470-2045(14)70314-6

@article{81cebf384145470f8f26331c0694e774,

title = "Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial",

author = "W. Taal and H.M. Oosterkamp and A.M.E. Walenkamp and H.J. Dubbink and L.V. Beerepoot and M.C.J. Hanse and J. Buter and A.H. Honkoop and D. Boerman and {de Vos}, F.Y.F. and W.N.M. Dinjens and R.H. Enting and M.J.B. Taphoorn and {van den Berkmortel}, F.W.P.J. and R.L.H. Jansen and D. Brandsma and J.E.C. Bromberg and {van Heuvel}, I. and R.M. Vernhout and {van der Holt}, B. and {van den Bent}, M.J.",

year = "2014",

doi = "https://doi.org/10.1016/S1470-2045(14)70314-6",

language = "Undefined/Unknown",

volume = "15",

pages = "943--953",

journal = "lancet oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "9",

}

Taal, W, Oosterkamp, HM, Walenkamp, AME, Dubbink, HJ, Beerepoot, LV, Hanse, MCJ, Buter, J, Honkoop, AH, Boerman, D, de Vos, FYF, Dinjens, WNM, Enting, RH, Taphoorn, MJB, van den Berkmortel, FWPJ, Jansen, RLH, Brandsma, D, Bromberg, JEC, van Heuvel, I, Vernhout, RM, van der Holt, B & van den Bent, MJ 2014, 'Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial', lancet oncology, vol. 15, no. 9, pp. 943-953. https://doi.org/10.1016/S1470-2045(14)70314-6

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. / Taal, W.; Oosterkamp, H.M.; Walenkamp, A.M.E. et al.
In: lancet oncology, Vol. 15, No. 9, 2014, p. 943-953.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

AU - Taal, W.

AU - Oosterkamp, H.M.

AU - Walenkamp, A.M.E.

AU - Dubbink, H.J.

AU - Beerepoot, L.V.

AU - Hanse, M.C.J.

AU - Buter, J.

AU - Honkoop, A.H.

AU - Boerman, D.

AU - de Vos, F.Y.F.

AU - Dinjens, W.N.M.

AU - Enting, R.H.

AU - Taphoorn, M.J.B.

AU - van den Berkmortel, F.W.P.J.

AU - Jansen, R.L.H.

AU - Brandsma, D.

AU - Bromberg, J.E.C.

AU - van Heuvel, I.

AU - Vernhout, R.M.

AU - van der Holt, B.

AU - van den Bent, M.J.

PY - 2014

Y1 - 2014

U2 - https://doi.org/10.1016/S1470-2045(14)70314-6

DO - https://doi.org/10.1016/S1470-2045(14)70314-6

M3 - Article

SN - 1470-2045

VL - 15

SP - 943

EP - 953

JO - lancet oncology

JF - lancet oncology

IS - 9

ER -